

mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised patients.

Elena Azzolini, Chiara Pozzi, Luca Germagnoli, Bianca Oresta, Nicola Carriglio, Mariella Calleri, Carlo Selmi, Maria De Santis, Silvia Finazzi, Carmelo Carlo-Stella, Alexia Bertuzzi, Francesca Motta, Angela Ceribelli, Alberto Mantovani, Fabrizio Bonelli, and Maria Rescigno

DOI: https://doi.org/10.26508/lsa.202201381

Corresponding author(s): Maria Rescigno, Humanitas University

Review Timeline:	Submission Date:	2022-01-21
	Editorial Decision:	2022-01-21
	Revision Received:	2022-02-02
	Editorial Decision:	2022-02-03
	Revision Received:	2022-02-04
	Accepted:	2022-02-07

Scientific Editor: Eric Sawey, PhD

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

Please note that the manuscript was previously reviewed at another journal and the reports were taken into account in the decision-making process at *Life Science Alliance*. Since the original reviews are not subject to Life Science Alliance's transparent review process policy, the reports and author response cannot be published.

1st Editorial Decision January 21, 2022

January 21, 2022

Re: Life Science Alliance manuscript #LSA-2022-01381-T

Prof. Maria Rescigno Humanitas University Department of Biomedical Sciences Pieve Emanuele, MI Italy

Dear Dr. Rescigno.

Thank you for submitting your manuscript entitled "A booster dose of mRNA-based COVID-19 vaccines fosters the development of an immune response in immunosuppressed fragile patients" to Life Science Alliance. We invite you to re-submit the manuscript, revised to address the Reviewer comments as you've outlined.

To upload the revised version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex

You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.

Please note that papers are generally considered through only one revision cycle.

When submitting the revision, please include a letter addressing the reviewers' comments point by point.

Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.

Sincerely,

Eric Sawey, PhD Executive Editor Life Science Alliance http://www.lsajournal.org

A. THESE ITEMS ARE REQUIRED FOR REVISIONS

- -- A letter addressing the reviewers' comments point by point.
- -- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
- -- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors
- -- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
- -- By submitting a revision, you attest that you are aware of our payment policies found here: https://www.life-science-alliance.org/copyright-license-fee

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and

spreadsheets for the main figures of the manuscript. If you would like to add sour	rce data, we would welcome one PDF/Excel-file
per figure for this information. These files will be linked online as supplementary '	"Source Data" files.

IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.

1st Revision - Editorial Decision February 3, 2022

February 3, 2022

RE: Life Science Alliance Manuscript #LSA-2022-01381-TR

Prof. Maria Rescigno Humanitas University Department of Biomedical Sciences Via Rita Levi Montalcini, 4 Pieve Emanuele, MI 20072 Italy

Dear Dr. Rescigno,

Thank you for submitting your revised manuscript entitled "mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised patients.". We would be happy to publish your paper in Life Science Alliance pending final revisions necessary to meet our formatting guidelines.

Along with points mentioned below, please tend to the following:

- -please upload your main manuscript text as an editable doc file;
- -please upload your main and supplementary figures as single files;
- -please add ORCID ID for the corresponding author-you should have received instructions on how to do so
- -please add the Twitter handle of your host institute/organization as well as your own or/and one of the authors in our system
- -please add your main, supplementary figure, and table legends to the main manuscript text after the references section
- -we encourage you to revise the figure legend for figure S3 such that the figure panels are introduced in alphabetical order
- -please upload your Tables in editable .doc or excel format
- -please add callouts for Figures S5A-B and S6A-B to your main manuscript text

If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.

LSA now encourages authors to provide a 30-60 second video where the study is briefly explained. We will use these videos on social media to promote the published paper and the presenting author (for examples, see https://twitter.com/LSAjournal/timelines/1437405065917124608). Corresponding or first-authors are welcome to submit the video. Please submit only one video per manuscript. The video can be emailed to contact@life-science-alliance.org

To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.

A. FINAL FILES:

These items are required for acceptance.

- -- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
- -- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors
- -- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file

per figure for this information. These files will be linked online as supplementary "Source Data" files.

- **Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.**
- **It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.**
- **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.**
- **Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.**

Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.

Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.

Sincerely,

Eric Sawey, PhD Executive Editor Life Science Alliance http://www.lsajournal.org

February 7, 2022

RE: Life Science Alliance Manuscript #LSA-2022-01381-TRR

Prof. Maria Rescigno Humanitas University Department of Biomedical Sciences Via Rita Levi Montalcini, 4 Pieve Emanuele, MI 20072 Italy

Dear Dr. Rescigno,

Thank you for submitting your Research Article entitled "mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised patients.". It is a pleasure to let you know that your manuscript is now accepted for publication in Life Science Alliance. Congratulations on this interesting work.

The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.

Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.

Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.

DISTRIBUTION OF MATERIALS:

Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.

You can contact the journal office with any questions, contact@life-science-alliance.org

Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.

Sincerely,

Eric Sawey, PhD Executive Editor Life Science Alliance http://www.lsajournal.org